BioGend Therapeutics Co., Ltd.
6733
Rank in Stocks
#20409
This company specializes in the development of innovative regenerative... This company specializes in the development of innovative regenerative bio-orthopedic products. Its current pipeline includes BiG-001 and BiG-006, both of which are osteoinductive bone graft substitutes. Additionally, it is advancing BiG-009, an autologous cartilage repair system. Established in 2016, the firm's operations are based in Taipei, Taiwan.
Share Price
$0.63255252
Last synced: 2026-11-10
Market Cap
$84.96M
Change (1 day)
-1.19%
Change (1 year)
-50.37%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade BioGend Therapeutics Co., Ltd. (6733)
Category
Healthcare
Operating Margin for BioGend Therapeutics Co., Ltd. (6733)
Operating Margin as of November 2026 TTM: -38.83%
According to BioGend Therapeutics Co., Ltd.'s latest financial reports, its current operating margin (TTM) is -38.83%. At the end of 2025 the company had an operating margin of -49.70%.
Operating Margin history for BioGend Therapeutics Co., Ltd. from 2019 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -38.83% | -21.87% |
| 2025 | -49.70% | -31.85% |
| 2024 | -72.93% | -54.60% |
| 2023 | -160.63% | -76.37% |
| 2022 | -679.91% | -56.31% |
| 2021 | -1,556.25% | -85.11% |
| 2020 | -10,451.47% | -8.63% |
| 2019 | -11,438.26% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.99% |
US
|
|
| -149.01% | -96.16% |
US
|
|
| 25.57% | -100.66% |
AU
|
|
| 31.23% | -100.80% |
BE
|
|
| 29.35% | -100.76% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about BioGend Therapeutics Co., Ltd.'s operating margin
What is BioGend Therapeutics Co., Ltd.'s operating margin?
BioGend Therapeutics Co., Ltd.'s operating margin is -38.83%, as of Nov 2026.
What was BioGend Therapeutics Co., Ltd.'s operating margin in 2025?
In 2025, BioGend Therapeutics Co., Ltd.'s operating margin was -49.70%, compared with -72.93% in 2024.
How has BioGend Therapeutics Co., Ltd.'s operating margin changed since 2020?
From 2020 to 2025, BioGend Therapeutics Co., Ltd.'s operating margin was highest in 2025 (-49.70%) and lowest in 2020 (-10,451.47%).
How does BioGend Therapeutics Co., Ltd.'s operating margin compare with similar companies?
BioGend Therapeutics Co., Ltd.'s operating margin (-38.83%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.